S&P 500   5,253.05 (+0.09%)
DOW   39,778.57 (+0.05%)
QQQ   444.26 (-0.13%)
AAPL   171.75 (-0.90%)
MSFT   420.59 (-0.20%)
META   487.76 (-1.24%)
GOOGL   150.99 (+0.08%)
AMZN   180.23 (+0.22%)
TSLA   176.83 (-1.67%)
NVDA   904.20 (+0.19%)
NIO   4.52 (-3.21%)
AMD   180.34 (+0.42%)
BABA   72.47 (+1.23%)
T   17.65 (+0.57%)
F   13.22 (+1.23%)
MU   117.82 (-1.11%)
CGC   8.60 (-9.95%)
GE   175.08 (-2.80%)
DIS   122.45 (+1.22%)
AMC   3.67 (-15.44%)
PFE   27.93 (+0.54%)
PYPL   67.09 (+0.78%)
XOM   116.14 (+1.02%)
S&P 500   5,253.05 (+0.09%)
DOW   39,778.57 (+0.05%)
QQQ   444.26 (-0.13%)
AAPL   171.75 (-0.90%)
MSFT   420.59 (-0.20%)
META   487.76 (-1.24%)
GOOGL   150.99 (+0.08%)
AMZN   180.23 (+0.22%)
TSLA   176.83 (-1.67%)
NVDA   904.20 (+0.19%)
NIO   4.52 (-3.21%)
AMD   180.34 (+0.42%)
BABA   72.47 (+1.23%)
T   17.65 (+0.57%)
F   13.22 (+1.23%)
MU   117.82 (-1.11%)
CGC   8.60 (-9.95%)
GE   175.08 (-2.80%)
DIS   122.45 (+1.22%)
AMC   3.67 (-15.44%)
PFE   27.93 (+0.54%)
PYPL   67.09 (+0.78%)
XOM   116.14 (+1.02%)
S&P 500   5,253.05 (+0.09%)
DOW   39,778.57 (+0.05%)
QQQ   444.26 (-0.13%)
AAPL   171.75 (-0.90%)
MSFT   420.59 (-0.20%)
META   487.76 (-1.24%)
GOOGL   150.99 (+0.08%)
AMZN   180.23 (+0.22%)
TSLA   176.83 (-1.67%)
NVDA   904.20 (+0.19%)
NIO   4.52 (-3.21%)
AMD   180.34 (+0.42%)
BABA   72.47 (+1.23%)
T   17.65 (+0.57%)
F   13.22 (+1.23%)
MU   117.82 (-1.11%)
CGC   8.60 (-9.95%)
GE   175.08 (-2.80%)
DIS   122.45 (+1.22%)
AMC   3.67 (-15.44%)
PFE   27.93 (+0.54%)
PYPL   67.09 (+0.78%)
XOM   116.14 (+1.02%)
S&P 500   5,253.05 (+0.09%)
DOW   39,778.57 (+0.05%)
QQQ   444.26 (-0.13%)
AAPL   171.75 (-0.90%)
MSFT   420.59 (-0.20%)
META   487.76 (-1.24%)
GOOGL   150.99 (+0.08%)
AMZN   180.23 (+0.22%)
TSLA   176.83 (-1.67%)
NVDA   904.20 (+0.19%)
NIO   4.52 (-3.21%)
AMD   180.34 (+0.42%)
BABA   72.47 (+1.23%)
T   17.65 (+0.57%)
F   13.22 (+1.23%)
MU   117.82 (-1.11%)
CGC   8.60 (-9.95%)
GE   175.08 (-2.80%)
DIS   122.45 (+1.22%)
AMC   3.67 (-15.44%)
PFE   27.93 (+0.54%)
PYPL   67.09 (+0.78%)
XOM   116.14 (+1.02%)
NASDAQ:CYRX

Cryoport (CYRX) Stock Price, News & Analysis

$17.75
-0.37 (-2.04%)
(As of 02:22 PM ET)
Today's Range
$17.70
$18.34
50-Day Range
$14.27
$18.12
52-Week Range
$9.00
$24.30
Volume
201,271 shs
Average Volume
457,894 shs
Market Capitalization
$869.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.29

Cryoport MarketRank™ Stock Analysis

Analyst Rating
Hold
2.17 Rating Score
Upside/​Downside
2.8% Upside
$18.29 Price Target
Short Interest
Bearish
8.80% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.52mentions of Cryoport in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$1.15 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.25) to ($1.09) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.39 out of 5 stars

Transportation Sector

110th out of 116 stocks

Pharmaceutical Preparations Industry

416th out of 433 stocks

CYRX stock logo

About Cryoport Stock (NASDAQ:CYRX)

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

CYRX Stock Price History

CYRX Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Cryoport (NASDAQ:CYRX) Trading Up 3.8%
Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
Cryoport (NASDAQ:CYRX) PT Raised to $17.00 at UBS Group
Analyst Ratings For CryoPort
Cryoport Tanks On Chilling Results And Bad Decisions
Cryoport, Inc. (CYRX)
Recap: CryoPort Q4 Earnings
CryoPort earnings: here's what Wall Street expects
CryoPort Inc CYRX
Matson, Inc. (MATX)
See More Headlines
Receive CYRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cryoport and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CYRX
Employees
1,170
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.29
High Stock Price Target
$28.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+0.9%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
6 Analysts

Profitability

Net Income
$-99,590,000.00
Pretax Margin
-42.59%

Debt

Sales & Book Value

Annual Sales
$233.26 million
Cash Flow
$0.41 per share
Book Value
$9.45 per share

Miscellaneous

Free Float
43,834,000
Market Cap
$887.52 million
Optionable
Optionable
Beta
1.61
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

CYRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Cryoport stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cryoport in the last twelve months. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CYRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CYRX, but not buy additional shares or sell existing shares.
View CYRX analyst ratings
or view top-rated stocks.

What is Cryoport's stock price target for 2024?

6 equities research analysts have issued 12-month price objectives for Cryoport's shares. Their CYRX share price targets range from $10.00 to $28.00. On average, they predict the company's share price to reach $18.29 in the next twelve months. This suggests a possible upside of 2.8% from the stock's current price.
View analysts price targets for CYRX
or view top-rated stocks among Wall Street analysts.

How have CYRX shares performed in 2024?

Cryoport's stock was trading at $15.49 on January 1st, 2024. Since then, CYRX shares have increased by 14.8% and is now trading at $17.79.
View the best growth stocks for 2024 here
.

Are investors shorting Cryoport?

Cryoport saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 4,170,000 shares, an increase of 6.6% from the February 29th total of 3,910,000 shares. Based on an average trading volume of 440,000 shares, the days-to-cover ratio is presently 9.5 days. Currently, 8.8% of the shares of the stock are sold short.
View Cryoport's Short Interest
.

When is Cryoport's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CYRX earnings forecast
.

How were Cryoport's earnings last quarter?

Cryoport, Inc. (NASDAQ:CYRX) posted its quarterly earnings results on Wednesday, November, 8th. The company reported ($0.31) earnings per share for the quarter, hitting the consensus estimate of ($0.31). The business had revenue of $56.16 million for the quarter, compared to analysts' expectations of $55.24 million. Cryoport had a negative net margin of 42.69% and a negative trailing twelve-month return on equity of 11.86%. The company's revenue for the quarter was down 7.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.15) EPS.

What guidance has Cryoport issued on next quarter's earnings?

Cryoport updated its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $242.0 million-$252.0 million, compared to the consensus revenue estimate of $253.2 million.

What other stocks do shareholders of Cryoport own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cryoport investors own include Gilead Sciences (GILD), Advanced Micro Devices (AMD), Micron Technology (MU), NVIDIA (NVDA), Taiwan Semiconductor Manufacturing (TSM), Amarin (AMRN), QUALCOMM (QCOM), Enterprise Products Partners (EPD), Pfizer (PFE) and Block (SQ).

Who are Cryoport's major shareholders?

Cryoport's stock is owned by many different institutional and retail investors. Top institutional investors include Brown Capital Management LLC (13.80%), Vanguard Group Inc. (7.47%), Vanguard Group Inc. (7.47%), Cadian Capital Management LP (7.08%), Massachusetts Financial Services Co. MA (4.07%) and New York State Common Retirement Fund (3.36%). Insiders that own company stock include Daniel M Hancock, Daniel M Hancock, Edward J Zecchini, Freeze Parent LP Blackstone, Jerrell Shelton, Mark W Sawicki, Michael R Egeck, Ramkumar Mandalam, Richard J Berman, Robert J Hariri and Robert Stefanovich.
View institutional ownership trends
.

How do I buy shares of Cryoport?

Shares of CYRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CYRX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners